Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guidelines
Image in Nephrology
Images in Nephrology
Letter to Editor
Letter to the Editor
Letters to Editor
Literature Review
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guidelines
Image in Nephrology
Images in Nephrology
Letter to Editor
Letter to the Editor
Letters to Editor
Literature Review
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
View/Download PDF

Translate this page into:

Letter to the Editor
34 (
2
); 205-205
doi:
10.4103/ijn.ijn_234_23

Seven-year Follow-up of India’s First Sequential Hematopoietic Stem Cell and Kidney Transplant for Multiple Myeloma

Professor, Department of Nephrology, AIIMS, Delhi, India
Consultant Medical Oncology, Artemis Hospital, Gurgaon, Haryana, India
Corresponding author: Dr. Dipankar Bhowmik, Department of Nephrology, All India Institute of Medical Sciences, New Delhi - 110 029, India. E-mail: dmbhowmik@aiims.edu
Licence
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Bhowmik D, Kumar L. Seven-year Follow-up of India’s First Sequential Hematopoietic Stem Cell and Kidney Transplant for Multiple Myeloma. Indian J Nephrol. 2024;34:205. doi: 10.4103/ijn.ijn_234_23

Dear Editor,

Chronic kidney disease is not uncommon in multiple myeloma patients. However, hematopoietic stem cell transplant (HSCT) is not usually done in dialysis patients. Even rarer is subsequent renal transplantation in these patients. We had earlier reported in IJN the first such case in India.1 The patient has now completed 90 months of follow-up posttransplant. Briefly, a 30-year-old female presented with rapidly progressive renal failure in Jan 2011. Renal biopsy revealed cast nephropathy. Bone marrow biopsy confirmed the diagnosis of kappa light chain plasma cell dyscrasia. After remission, autologous HSCT was done on 06.06.2014. Subsequently, renal transplantation was done on 04.01.2016 without induction therapy, the donor being her father. Immunosuppression consisted of prednisolone, tacrolimus, and mycophenolate. She achieved a nadir serum creatinine of 0.8 mg%. One year later, she had parvovirus B19 infection with graft dysfunction, which was successfully treated with intravenous immunoglobulin. Kidney biopsy showed features of calcineurin inhibitor toxicity. Tacrolimus was substituted by cyclosporine. Serum protein electrophoresis and free light chain assay were monitored initially at three-monthly intervals and, subsequently, at six-monthly intervals to date, which were always negative. Posttransplant, she also had two episodes of urinary tract infection. Two months back, she had an episode of lower respiratory tract infection with graft dysfunction. After resolution of infection, her renal functions recovered to the baseline serum creatinine of 1.0 mg/dl. Currently, she continues to be on prednisolone, cyclosporine, and mycophenolate. The cyclosporine serum C0 level is 72 ng/ml.

A study of 12 patients with a median follow-up of 40 months showed hematologic progression in 75% patients and a mortality of 45.5%.2 In a recent review of 36 patients with a median follow-up of 48 months, 69% were alive and 36% had relapse of multiple myeloma.3 After 90 months of post-renal transplant follow-up, our patient remains disease free with normal renal functions.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Conflicts of interest

There are no conflicts of interest.

Financial support and sponsorship

Nil.

References

  1. , , , , , . Sequential, autologous hematopoietic stem cell transplant followed by renal transplant in multiple myeloma. Indian J Nephrol. 2017;27:324-6.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Kidney transplant outcomes of patients with multiple myeloma. Kidney Int Rep. 2022;7:752-62.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Kidney transplantation in patients with multiple myeloma: Narrative analysis and review of the last two decades. Nephrol Dial Transplant. 2022;37:1616-26.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
72

PDF downloads
40
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections